Results of a questionnaire on the treatment of patients with Behçet's syndrome: A trend for more intensive treatment

Clinical and Experimental Rheumatology

Volumn 30, Issue SUPPL.72, 2012, Pages

  Turkstra, Franktien ^a   van Vugt, Richard M ^b   Dijkmans, Ben A C ^a,b   Yazici, Yusuf ^c   Yazici, Hasan ^d  

^a Jan Van Breemen Research Institute/Reade   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c NYU HOSPITAL FOR JOINT DISEASES   (United States)

^d ISTANBUL UNIVERSITY CERRAHPASA   (Turkey)

Author keywords

Beh et's syndrome; Questionnaire; Treatment

Indexed keywords

AZATHIOPRINE; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; INFLIXIMAB; INTERFERON; STEROID; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; ANTICOAGULANT AGENT; IMMUNOSUPPRESSIVE AGENT;

ANTICOAGULANT THERAPY; ARTICLE; BEHCET DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CORTICOSTEROID THERAPY; DEEP VEIN THROMBOSIS; GEOGRAPHIC DISTRIBUTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTENSIVE CARE; MONOTHERAPY; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUESTIONNAIRE; RECEPTOR BLOCKING; RETINA VASCULITIS; TREND STUDY; UVEITIS; AGE; CLINICAL PRACTICE; CONSENSUS; DISEASE COURSE; EVIDENCE BASED MEDICINE; HEALTH CARE SURVEY; PATIENT SELECTION; REMISSION; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; TREATMENT OUTCOME;

AGE FACTORS; ANTICOAGULANTS; BEHCET SYNDROME; CONSENSUS; DISEASE PROGRESSION; EVIDENCE-BASED MEDICINE; GUIDELINE ADHERENCE; HEALTH CARE SURVEYS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PATIENT SELECTION; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; QUESTIONNAIRES; REMISSION INDUCTION; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; TREATMENT OUTCOME;

EID: 84873264589     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. YAZICI H, BARNES CG. A survey of treatment in Behçet's syndrome. In: O'DUFFY JD, KOKMEN E (Eds) Behçet's disease. Basic and clinical aspects. Marcel Dekker Inc., New York. 1991.
2. YAZICI H, YURDAKUL S, HAMURYUDAN V. The management of Behçet's syndrome: How are we doing? Clin Exp Rheum 1999; 17: 145-7.
3. HATEMI G, SILMAN A, BANG D et al. EULAR EXPERT COMMITTEE: EULAR recommendations for the management of Behçet's disease. Ann Rheum Dis 2008; 67: 1656-62.
4. KLARENBEEK NB, GÜLER-YÜKSEL M, VAN DER KOOIJ SM et al. The impact of four dynamic, goal-steered treatment strategies on the 5-year outcome of rheumatoid arthritis patients in the BeSt study. Ann Rheum Dis 2011; 70: 1039-46..
5. HATEMI G, SILMAN A, BANG D et al. Management of Behçet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet disease. Ann Rheum Dis 2009; 68: 1528-34.
6. AHN JK, LEE YS, JEON CH, KOH EM, CHA HS Treatment of venous thrombosis associated with Behçet's disease: immunosuppressive therapy alone versus immuno-suppressive therapy plus anticoagulation. Clin Rheumatol 2008; 27: 201-5.
7. KORKMAZ C, KASIFOGLU T, KEBAPCI M Budd-Chiari syndrome in the course of Behçet's disease: clinical and laboratory analysis of 4 cases. Joint Bone Spine 2007; 74: 245-8.